Finance Watch: Biopharma IPOs On The Upswing, Including Ex-US Offerings

Mineralys, Inventiva Carry Out Complex Financings

  
Generate a summary of this article
Listen to this article
Beta

ghghghghghjhjhjhj

The market for biopharmaceutical initial public offerings is still far from ramping up to the boom years of 2020 and 2021, but with 12 IPOs as of Parabilis Medicines’ record-breaking launch on June 9, drug developers have launched just as many first-time offerings in the US in 2026 as they did by year-end in 2025. And while the number of IPOs remains below the industry’s record of 107 offerings in 2021, companies are raising large sums to advance later-stage drug candidates and ex-US markets are becoming receptive to biopharma IPOs.

Parabilis grossed $670m initially, plus $75m from a concurrent private placement, but the cancer drug developer’s...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Scrip

Easy Access To GLP-1s Is Causing Big Problems For Obesity Studies

in the expanding and competitive field of obesity therapy clinical trials, one trend is increasingly causing a headache: placebo-arm participants dropping out or using “off-protocol” weight-loss treatments while on trial.

Test

Sponsored by :

Clinical Trial Complexity Is Reshaping Evidence Collection Clinical trial innovation has historical

As clinical trials grow more complex, execution pressures are changing where and how evidence is collected.

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

More from